A Prospective Cohort Real-World Study of lutetium-177 (177Lu)-DOTATATE radionuclide therapy in patients with Neuroendocrine Tumor
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Dec 2022 New trial record